menu search

HRMY / Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million

Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million
Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would acquire the cannabinoid therapy company in a deal worth up to $200 million. Harmony, which specializes in therapies for rare neurological diseases, said it would acquire all outstanding shares of Zynerba for $1.1059 per share in cash, or $60 million in the aggregate, with potential additional payments of up to $140 million based on achievement of certain clinical, regulatory and sales milestones. Read More
Posted: Aug 14 2023, 09:18
Author Name: Market Watch
Views: 121322

HRMY News  

HRMY vs. REGN: Which Stock Should Value Investors Buy Now?

By Zacks Investment Research
November 3, 2023

HRMY vs. REGN: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Rege more_horizontal

Harmony Stock Tanks On Study Miss For Narcolepsy Drug: Problems May Be Escalating

By Seeking Alpha
October 13, 2023

Harmony Stock Tanks On Study Miss For Narcolepsy Drug: Problems May Be Escalating

Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings more_horizontal

Why Shares of Harmony Bioscience Are Falling on Friday

By The Motley Fool
October 13, 2023

Why Shares of Harmony Bioscience Are Falling on Friday

Harmony has already gotten approval for the drug to treat adults with excessive daytime sleepiness who have narcolepsy. Harmony's second-quarter reven more_horizontal

Harmony Biosciences stock drops on disappointing study results

By Proactive Investors
October 13, 2023

Harmony Biosciences stock drops on disappointing study results

Harmony Biosciences Holdings Inc shares sank 38% to $18.66 in late-morning trading on Friday after the pharmaceutical company reported topline results more_horizontal

Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep

By Seeking Alpha
September 24, 2023

Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep

Harmony Biosciences has experienced strong and profitable growth following the approval and commercialization of WAKIX. The company's success has allo more_horizontal

HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE

By PRNewsWire
September 13, 2023

HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE

PLYMOUTH MEETING, Pa. , Sept. 13, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutica more_horizontal

Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million

By Market Watch
August 14, 2023

Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million

Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would more_horizontal

Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates

By Zacks Investment Research
August 1, 2023

Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.62 per share more_horizontal


Search within

Pages Search Results: